You are here

  • Home
  • Archive
  • Volume 78, Issue 11
  • Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez

Article metrics

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez
Free

 

Online download statistics by month:

Online download statistics by month: October 2018 to March 2024

AbstractFullPdf
Oct 201821222552
Nov 2018285332202
Dec 201835235222
Jan 201921321220
Feb 201940440410
Mar 201949749723
Apr 201947747710
May 201948648621
Jun 20193013016
Jul 201922322419
Aug 201920720612
Sep 201928828813
Oct 201929629743
Nov 2019939219
Dec 2019424223
Jan 2020363325
Feb 202026267
Mar 202041398
Apr 2020424117
May 2020212125
Jun 202031269
Jul 2020272411
Aug 2020161611
Sep 202034277
Oct 202023248
Nov 202023228
Dec 2020262610
Jan 2021191713
Feb 202110109
Mar 202120207
Apr 202129298
May 202146446
Jun 202120201
Jul 2021363611
Aug 202131307
Sep 2021363415
Oct 2021262218
Nov 2021252515
Dec 202133306
Jan 202231298
Feb 202228282
Mar 2022434411
Apr 202231315
May 202241408
Jun 202234346
Jul 202245444
Aug 202247466
Sep 2022434317
Oct 202237376
Nov 202227287
Dec 202243425
Jan 202331307
Feb 202354544
Mar 202325263
Apr 202313114
May 2023101010
Jun 2023882
Jul 202319187
Aug 2023221711
Sep 202311112
Oct 2023995
Nov 202311115
Dec 202318183
Jan 202429295
Feb 2024884
Mar 20246631
Total57775789945